Načítá se...
The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis
BACKGROUND: The non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94–8862) has been used to treat chronic heart failure (CHF) with reduced ejection fraction (HFrEF). However, conflicting results were reported for its efficacy and safety. The study aimed to compare the efficacy and...
Uloženo v:
| Vydáno v: | Medicine (Baltimore) |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Health
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916685/ https://ncbi.nlm.nih.gov/pubmed/29668577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000010254 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|